Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Building Tomorrow Together: What We Are Looking Forward to at CtUC 2024

Censis Technologies previews what sterile processing and perioperative healthcare leaders can expect at the CtUC 2024 user conference. The event brings together industry professionals to explore innovation, best practices, and collaboration in sterile processing. Attendees can expect sessions focused on shaping the future of perioperative care through technology and shared expertise.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Censis on MarketScale.

By Healthcare · Censis TechnologiesCensis Technologies Users Conference 2024Harshil GoradiaShena Moore
Share

Key takeaways

01

CtUC 2024 is a user conference hosted by Censis Technologies focused on sterile processing and perioperative healthcare.

02

The event emphasizes collaboration among sterile processing leaders to drive innovation and best practices.

03

Sessions are designed to help healthcare facilities advance their use of Censis technology and improve patient safety outcomes.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Get ready for the event of the year—Censis Technologies Users Conference 2024! This groundbreaking conference is where the sterile processing community comes together to ignite innovation, build powerful connections, and elevate healthcare to new heights. If you're a technician, manager, or industry expert within the perioperative loop, this is the must-attend event of the year! With the theme, "Building Tomorrow: Innovate, Empower, Thrive," CtUC 2024 promises to be an unforgettable experience, bringing together thought leaders, cutting-edge technology, and industry-changing insights that will shape the future of healthcare.

Censis Technologies' leadership is thrilled about what this year's conference will offer. In this episode of ConCensis, host Gabrielle Bejarano sat down with Sheena Moore, the President of Censis Technologies, Yizhou Chen, the VP of Product and Marketing, and Harshil Goradia, the Chief Technology Officer.

Sheena Moore is gearing up for her first-ever CtUC, and she's fired up about the potential this event holds. For her, CtUC 2024 is all about learning from clients and pushing the boundaries of innovation. This is your chance to be part of something bigger, where new technologies will be unveiled, challenges will be tackled head-on, and the focus will remain on the ultimate goal: delivering superior patient care across the globe.

This is your chance to be part of something bigger, where new technologies will be unveiled, challenges will be tackled head-on, and the focus will remain on the ultimate goal: delivering superior patient care across the globe.

Yizhou Chen is excited to dive into the heart of what makes Censis tick—its customers. At CtUC 2024, you'll experience firsthand how Censis collaborates with its clients to create solutions that don't just meet the present needs but anticipate the future. Innovation isn't just a buzzword here—it's the driving force behind every product and service. Expect to leave CtUC 2024 with new insights, tools, and a network that empowers you to solve problems, improve workflows, and enhance patient outcomes like never before.

Expect to leave CtUC 2024 with new insights, tools, and a network that empowers you to solve problems, improve workflows, and enhance patient outcomes like never before.

Harshil Goradia promises that CtUC 2024 will put innovation in the spotlight, especially with AI and advanced technologies that are transforming the sterile processing industry. With a commitment to accelerating product development and enhancing customer support, Censis is leading the charge in revolutionizing healthcare. Don't miss your chance to be a part of this exciting journey, where cutting-edge technology meets real-world application, and where you'll walk away empowered to make a real impact in your organization. CtUC 2024 is set to be a game-changer—be there to witness it!

Censis

Part of this channel

Censis

Surgical instrument management software for over 1,300 U.S. hospitals.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

H
Healthcare
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512